Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a major public health problem with growing prevalence and poor outcomes, mainly due to the lack of an effective treatment. HFpEF pathophysiology is heterogeneous and complex. Recently a “new paradigm” has been proposed, suggesting that cardio...
Main Authors: | Francesca Graziani, Rosa Lillo, Filippo Crea |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.678530/full |
Similar Items
-
Heart failure with preserved ejection fraction – onset
by: Branimir Kanazirev
Published: (2021-07-01) -
Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
by: Anthony E. Peters, et al.
Published: (2021-04-01) -
Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
by: Chao Ma, et al. -
Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
by: Chiara Borrelli, et al.
Published: (2019-09-01) -
Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction
by: Christian Besler, et al.
Published: (2021-06-01)